Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epigenomics' tamoxifen response study "inconclusive"

This article was originally published in Clinica

Executive Summary

Shares in Epigenomics fell by over 15% this week (October 31) after the company reported "inconclusive" data from a key study evaluating its tamoxifen treatment response test for breast cancer. The setback is expected to delay the company's product by at least nine months and could potentially complicate its long-term DNA methylation development programme with partner Roche Diagnostics.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel